USPTO trademark

LYMDEVRA

AllowedUSPTOWord markClass 5

"LYMDEVRA" is a word mark owned by Sarepta Therapeutics, Inc., filed at the USPTO on October 21, 2025. It has been allowed and covers class 5 (Pharmaceuticals).

View Sarepta Therapeutics, Inc. portfolioGet this data via the API
Official USPTO record
LYMDEVRA trademark as filed
As filed with the USPTO
Status
Allowed
Since June 9, 2026
Filed
October 21, 2025
Registered
Not yet
Expires
Not recorded
Application no.
99454183
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
1 class
Ownership

Who owns LYMDEVRA

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Sarepta Therapeutics, Inc.

SRPT · Cambridge, United States

215 trademarks in the portfolioView company

Representative

Maury M. Tepper, III

Tepper & Eyster, PLLC

Goods and services

What the mark covers

The products and services LYMDEVRA is filed for, grouped by Nice class.

  • Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations containing viral vectors for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations for gene therapy, gene editing, and genome editing for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Gene therapies, in the nature of pharmaceutical preparations, for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Noa e-mailed - sou required from applicant
  2. Official gazette publication confirmation e-mailed
  3. Published for opposition
  4. Notification of notice of publication e-mailed
  5. Approved for pub - principal register
  6. Assigned to examiner
  7. Application filing receipt mailed
  8. New application office supplied data entered
  9. New application entered
FAQ

About LYMDEVRA

Who owns the trademark "LYMDEVRA"?

The USPTO trademark "LYMDEVRA" (application 99454183) is owned by Sarepta Therapeutics, Inc.

What is the status of "LYMDEVRA"?

Its status at the USPTO is: allowed.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull LYMDEVRA and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2b4a-43b7-76f3-9406-d0a8b1e67354
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2b4a-43b7-76f3-9406-d0a8b1e67354",
  "object": "trademark",
  "mark_text": "LYMDEVRA",
  "status": {
    "primary": "pending",
    "stage": "allowed"
  },
  "office_code": "US",
  "application_number": "99454183",
  "filing_date": "2025-10-21",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Sarepta Therapeutics, Inc.",
      "entity_id": "ent_019ebbb7-51a3-7732-89ae-4e7311f24a9c"
    }
  ]
}